Point72 Hong Kong’s HilleVax HLVX Stock Holding History

Point72 Hong Kong’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,950	Closed	-$76K	–	2130
2022 Q2	$76K	Buy	+6,950	New	+$82.5K	﹤0.01%	1260

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Hong Kong's HLVX Position: Q3 2022 in Review

Point72 Hong Kong sold out of HilleVax (HLVX) in Q3 2022, closing a stake of 6,950 shares — an estimated $76K sold.

Point72 Hong Kong first reported a position in HLVX in Q2 2022 and held it in 1 quarter. The position peaked at $76K in Q2 2022. 51 funds tracked by Wall St. Rank hold HLVX as of Q3 2022.

Point72 Hong Kong reported no remaining HilleVax position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 6,950 HilleVax shares in Q3 2022, an estimated $76K.
Point72 Hong Kong first reported a position in HilleVax in Q2 2022 and held it in 1 quarter.
Point72 Hong Kong's HilleVax position peaked at $76K in Q2 2022.
51 funds tracked by Wall St. Rank held HilleVax as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.